Anti-infectives Research & Innovation Vienna Austria
Innovative therapies for acute and
life-threatening bacterial infections
addressing antimicrobial resistance
We are a privately-held biopharmaceutical company dedicated to innovation, research and development of novel anti-infectives offering solutions for the global problem of antimicrobial resistance (AMR)
About Us
Addressing the
Major Unmet Medical Need for Medications Overcoming Resistance
ARIVA Med was founded in 2024 by the R&D Leaders of Nabriva Therapeutics to continue the R&D success story of pleuromutilin research. Pleuromutilins are protein synthesis inhibitors and lefamulin is the first-in-class pleuromutilin for oral and intravenous use in human. As part of the Nabriva team the ARIVA Med founders have developed lefamulin from discovery through clinical phases up to approval by the EMA and the US FDA and beyond.
Pipeline
The ARIVA Med team has in-depth knowledge about pleuromutilin and cephalosporin structure-activity relationship, and an extensive compound library and database. More than 20 years of experience and a strong track-record comprising all phases of drug development are the basis for proceeding the ARIVA Med programs.
Our antibacterial lead compounds belong to the classes of epimutilins, pleuromutilins and cephalosporins and fight bacterial superbugs with focus on
- Antimicrobial resistance threats defined by
WHO and CDC - Neglected Diseases
- Biothreat organisms
- Emerging threats
- Dual-mode molecules with antibacterial and immunomodulatory activity
Partnering
We are actively seeking partnerships for the further development of our clinical and pre-clinical programs. We are open to various collaborations and would like to hear from you. Please
reach out!
Contact